ATGAM® Adverse Reactions

(lymphocyte immune globulin, anti-thymocyte globulin [equine])

6 ADVERSE REACTIONS

The most clinically significant adverse reactions are anaphylaxis, infection, thrombocytopenia, leukopenia, arthralgia, edema, bradycardia, and abnormal renal and liver function tests.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of ATGAM has been evaluated in 367 patients with renal allograft rejection and 109 patients with aplastic anemia.

The renal allograft rejection and aplastic anemia patients received a similar dosing regimen, and these data were pooled to obtain the frequencies listed in Tables 1 and 2 below.

The most commonly reported adverse reactions (occurring in greater than 10% of patients) are pyrexia, chills, rash, thrombocytopenia, leukopenia, and arthralgia.

Table 1. Adverse Reactions Occurring in ≥1% of Patients Who Received ATGAM
*
Percentages are treatment-emergent all-causality events
†
Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms

Adverse Reaction*,†

ATGAM

Frequency (%)

(N = 476)

Pyrexia

39.5

Chills

26.5

Rash

25.6

Thrombocytopenia

21.6

Leukopenia

17.9

Arthralgia

17.2

Urticaria

9.2

Headache

5.3

Pruritus

4.6

Nausea

4.2

Infection

3.4

Vomiting

3.4

Thrombophlebitis

3.2

Hypertension

2.9

Hypotension

2.9

Diarrhea

2.9

Abdominal pain upper

2.7

Chest pain

2.7

Infusion site pain

2.1

Edema

2.1

Bradycardia

1.5

Back pain

1.5

Lymphadenopathy

1.3

Arteriovenous fistula thrombosis

1.3

Dizziness

1.1

Dyspnea

1.1

Tachycardia

1.1

Liver function test abnormal

1.0

Table 2. Adverse Reactions Occurring in <1% of Patients Who Received ATGAM
*
Percentages are treatment-emergent all-causality events
†
Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms

Adverse Reaction*,†

ATGAM

Frequency (%)

(N = 476)

Convulsion

0.8

Pleural effusion

0.8

Night sweats

0.8

Serum sickness

0.6

Hyperglycemia

0.6

Stomatitis

0.6

Renal function test abnormal

0.6

Herpes simplex

0.4

Agitation

0.4

Hiccups

0.4

Proteinuria

0.4

Asthenia

0.4

Malaise

0.4

Wound dehiscence

0.4

Anaphylactic reaction

0.2

Encephalitis

0.2

Paresthesia

0.2

Renal artery thrombosis

0.2

Iliac vein occlusion

0.2

Laryngospasm

0.2

Pulmonary edema

0.2

Dermatitis allergic

0.2

Periorbital edema

0.2

Toxic epidermal necrolysis

0.2

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of ATGAM. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Infections and infestations: Sepsis, Hepatitis viral, Localized infection, Systemic infection (bacterial, viral, fungal).

Blood and lymphatic system disorders: Anemia, Eosinophilia, Granulocytopenia, Hemolysis, Hemolytic anemia, Neutropenia, Pancytopenia

Psychiatric disorders: Confusional state, Disorientation

Nervous system disorders: Dyskinesia, Syncope, Tremor

Cardiac disorders: Cardiac failure congestive

Vascular disorders: Deep vein thrombosis, Vasculitis

Respiratory, thoracic and mediastinal disorders: Apnea, Cough, Epistaxis, Oropharyngeal pain

Gastrointestinal disorders: Abdominal pain, Gastrointestinal hemorrhage, Gastrointestinal perforation, Oral pain

Skin and subcutaneous tissue disorders: Hyperhidrosis

Musculoskeletal and connective tissue disorders: Flank pain, Muscle rigidity, Myalgia, Pain in extremity

Renal and urinary disorders: Kidney enlargement, Kidney rupture, Renal failure acute

Congenital, familial and genetic disorders: Aplasia

General disorders and administration site conditions: Infusion site erythema, Infusion site swelling, Pain

Find ATGAM® medical information:

Find ATGAM® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

ATGAM® Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Adverse Reactions

6 ADVERSE REACTIONS

The most clinically significant adverse reactions are anaphylaxis, infection, thrombocytopenia, leukopenia, arthralgia, edema, bradycardia, and abnormal renal and liver function tests.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of ATGAM has been evaluated in 367 patients with renal allograft rejection and 109 patients with aplastic anemia.

The renal allograft rejection and aplastic anemia patients received a similar dosing regimen, and these data were pooled to obtain the frequencies listed in Tables 1 and 2 below.

The most commonly reported adverse reactions (occurring in greater than 10% of patients) are pyrexia, chills, rash, thrombocytopenia, leukopenia, and arthralgia.

Table 1. Adverse Reactions Occurring in ≥1% of Patients Who Received ATGAM
*
Percentages are treatment-emergent all-causality events
†
Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms

Adverse Reaction*,†

ATGAM

Frequency (%)

(N = 476)

Pyrexia

39.5

Chills

26.5

Rash

25.6

Thrombocytopenia

21.6

Leukopenia

17.9

Arthralgia

17.2

Urticaria

9.2

Headache

5.3

Pruritus

4.6

Nausea

4.2

Infection

3.4

Vomiting

3.4

Thrombophlebitis

3.2

Hypertension

2.9

Hypotension

2.9

Diarrhea

2.9

Abdominal pain upper

2.7

Chest pain

2.7

Infusion site pain

2.1

Edema

2.1

Bradycardia

1.5

Back pain

1.5

Lymphadenopathy

1.3

Arteriovenous fistula thrombosis

1.3

Dizziness

1.1

Dyspnea

1.1

Tachycardia

1.1

Liver function test abnormal

1.0

Table 2. Adverse Reactions Occurring in <1% of Patients Who Received ATGAM
*
Percentages are treatment-emergent all-causality events
†
Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms

Adverse Reaction*,†

ATGAM

Frequency (%)

(N = 476)

Convulsion

0.8

Pleural effusion

0.8

Night sweats

0.8

Serum sickness

0.6

Hyperglycemia

0.6

Stomatitis

0.6

Renal function test abnormal

0.6

Herpes simplex

0.4

Agitation

0.4

Hiccups

0.4

Proteinuria

0.4

Asthenia

0.4

Malaise

0.4

Wound dehiscence

0.4

Anaphylactic reaction

0.2

Encephalitis

0.2

Paresthesia

0.2

Renal artery thrombosis

0.2

Iliac vein occlusion

0.2

Laryngospasm

0.2

Pulmonary edema

0.2

Dermatitis allergic

0.2

Periorbital edema

0.2

Toxic epidermal necrolysis

0.2

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of ATGAM. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Infections and infestations: Sepsis, Hepatitis viral, Localized infection, Systemic infection (bacterial, viral, fungal).

Blood and lymphatic system disorders: Anemia, Eosinophilia, Granulocytopenia, Hemolysis, Hemolytic anemia, Neutropenia, Pancytopenia

Psychiatric disorders: Confusional state, Disorientation

Nervous system disorders: Dyskinesia, Syncope, Tremor

Cardiac disorders: Cardiac failure congestive

Vascular disorders: Deep vein thrombosis, Vasculitis

Respiratory, thoracic and mediastinal disorders: Apnea, Cough, Epistaxis, Oropharyngeal pain

Gastrointestinal disorders: Abdominal pain, Gastrointestinal hemorrhage, Gastrointestinal perforation, Oral pain

Skin and subcutaneous tissue disorders: Hyperhidrosis

Musculoskeletal and connective tissue disorders: Flank pain, Muscle rigidity, Myalgia, Pain in extremity

Renal and urinary disorders: Kidney enlargement, Kidney rupture, Renal failure acute

Congenital, familial and genetic disorders: Aplasia

General disorders and administration site conditions: Infusion site erythema, Infusion site swelling, Pain
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5Pm ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.